Clinical Trial

Study of JK07 in Patients With Chronic Heart Failure

Study acronym: RENEU-HF
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-04-12; most recent amendment 2026-05-19.
Status change: Recruiting → Active, Not Recruiting 2026-05-19
Trial Details
NCT Number NCT06369298
Lead Sponsor Salubris Biotherapeutics Inc
Conditions Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Enrollment 282 participants
Start Date 2024-03-28
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-22